

1624



CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313 on

2 May 2007 HUESCHEN AND SAGE

Michilan Con Dated: 2 May 2007

SERVIER 453 PCT

Applicant

Gérard COUDERT, Franck LEPIFRE, Daniel-Henri

CAIGNARD, Pierre RENARD, John HICKMAN, Alain

PIERRE, and Laurence KRAUS-BERTHIER

Serial No. :

10/531,648

Filed

April 15, 2005

Title :

SUBSTITUTED BENZO[e][1,4]OXAZINO[3,2-

g]ISOINDOLE COMPOUNDS

Art Unit

1624

Examiner:

Kahsay HABTE, Esq.

Honorable Commissioner for Patents PO Box 1450 Alexandria, VA 22313

RESPONSE AND ELECTION UNDER 37 CFR §§ 1.111 AND 1.142

Sir:

Responsive to the Office Action, a Restriction Requirement, dated April 11, 2007, it is the position of the Office that the application pertains to a plurality of patentably distinct inventions. It is the position of the Office that the Restriction **Groups I-II** do not relate to a single inventive concept since they are drawn to structurally different

compounds comprising patentably distinct core structures. It is the position of the Office that the core ring system of Restriction Group I is a pentacyclic ring system, and the core ring system of Restriction Group II is a tetracyclic ring system.

The Applicants *traverse* this conclusion on the grounds that one skilled in the chemical arts would recognize that the compounds of Restriction Group II are useful as intermediates in the synthesis of the compounds of Restriction Group I, and that these intermediates have the same structural core (i.e., the tetracyclic 1,4-oxazine core as defined by the Office) as the compounds of Restriction Group I. Thus, one skilled in the chemical arts would not find the instant invention to involve structurally distinct inventions. Absent contradictory evidence that those skilled in the art would find the instant invention to consist of multiple inventions, it is submitted that the Office Requirement is not substantiated.

Nonetheless, in an effort to advance the prosecution of the instant application, the Applicants elect *with traverse* to prosecute the invention of **Group I** (Claims 14-25), drawn to benzo[a]pyrrolo[3,4-c]phenoxazines or benzo[e]pyrido[1,4]-oxazino[3,2-g]indoles, of the Restriction Requirement.

Absent a favorable decision upon reconsideration of the Restriction Requirement, the Examiner may withdraw the non-elected subject matter, without prejudice to its rejoinder during later examination and/or prosecution in a Divisional Application.

Accordingly, entry of the present Election into the record of this application and favorable action on the merits thereof, are respectfully solicited.

Respectfully submitted,

THE FIRM OF HUESCHEN AND SAGE

MICHELE M. CUDAHY, Reg. No. 55,093



Dated: May 2, 2007 Customer No.: 25,666 Seventh Floor, Kalamazoo Building 107 West Michigan Avenue Kalamazoo, MI 49007 (269) 382-0030

Enclosure: Postal Card Receipt

THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FURTHER OR ADDITIONAL FEES WHICH MAY BE REQUIRED (DUE TO OMISSION, DEFICIENCY, OR OTHERWISE), OR TO CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NO. 08,3220.